RZLT Rezolute Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RZLT

Price (delayed)

$4

Market cap

$385.17M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.82

Enterprise value

$375.04M

?
Relative Growth: Rel. Growth: 12
Relative Strength: Rel. Strength: 62
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 5

Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, is designed to treat all ...

Highlights
Rezolute's quick ratio has soared by 89% YoY and by 12% from the previous quarter
RZLT's debt is down by 37% year-on-year and by 14% since the previous quarter
Rezolute's equity has increased by 41% YoY but it has decreased by 9% QoQ
Rezolute's net income has decreased by 12% YoY but it has increased by 3.3% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.rezolutebio.com
Peers: OPK ORGO

Key stats

What are the main financial stats of RZLT

RZLT stock price

How has the Rezolute stock price performed over time
Intraday
-0.99%
1 week
0.5%
1 month
-21.41%
1 year
-53.05%
YTD
69.49%
QTD
-23.08%

Financial performance

How have Rezolute's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$87.25M
Net income
-$81.49M
Gross margin
N/A
Net margin
N/A
Rezolute's operating income has decreased by 13% YoY but it has increased by 3% from the previous quarter
Rezolute's net income has decreased by 12% YoY but it has increased by 3.3% from the previous quarter

Price vs fundamentals

How does RZLT's price correlate with its fundamentals

Growth

What is Rezolute's growth rate over time

Valuation

What is Rezolute stock price valuation
P/E
N/A
P/B
3.28
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Rezolute's EPS has increased by 29% YoY and by 12% QoQ
The stock's price to book (P/B) is 95% more than its 5-year quarterly average of 1.7 and 7% more than its last 4 quarters average of 3.1
Rezolute's equity has increased by 41% YoY but it has decreased by 9% QoQ

Efficiency

How efficient is Rezolute business performance
The company's return on invested capital rose by 16% YoY and by 11% QoQ
The ROE is up by 16% year-on-year and by 9% since the previous quarter
RZLT's return on assets is up by 14% year-on-year and by 8% since the previous quarter

Dividends

What is RZLT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RZLT.

Financial health

How did Rezolute financials performed over time
Rezolute's quick ratio has soared by 89% YoY and by 12% from the previous quarter
Rezolute's current ratio has soared by 88% YoY and by 12% from the previous quarter
RZLT's debt is 99% smaller than its equity
RZLT's debt to equity has dropped by 50% year-on-year
Rezolute's equity has increased by 41% YoY but it has decreased by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.